Alerta

Method and system for detecting relation between full sibs and half sibs of poultry

Resumen de: CN121811960A

The invention discloses a poultry full-sib and half-sib relationship detection method and system, and relates to poultry breeding. The method comprises the following steps: obtaining samples of N poultry individuals in a poultry group to be detected, and extracting DNA (Deoxyribose Nucleic Acid); performing genetic typing on N poultry individuals by using a high-density SNP chip to obtain a genotype matrix M; performing quality control on the genotype matrix M, and filtering the SNP markers with the detection rate lower than a first preset threshold value or the minimum allele frequency MAF lower than a second preset threshold value to obtain a genotype matrix after quality control; according to the genotype matrix, calculating an IBS similarity coefficient and a genome genetic relationship coefficient GRC between any two individuals i and j; according to the poultry with known genetic relationship, IBS similarity coefficient distribution and genome genetic relationship coefficient GRC distribution of full-sib, half-sib and non-sib relationships are respectively counted, and 95% confidence interval of each category is calculated. The method improves the classification precision.

Differentiation Method for an Intestinal Epithelial Monolayer Model Derived from Duodenal Organoids of Crohns Disease Patients

Resumen de: KR20260045660A

본 발명은 크론병 환자 십이지장 오가노이드 유래 장 상피 단층 모델의 분화 방법에 관한 것으로, 발명의 장 상피 단층 모델은 3차원 십이지장 오가노이드로부터 해리된 단일 세포에 기초하여 분화를 유도한 것으로, 다양한 장 상피 세포 유형을 포함하고 내강(lumen)에 대한 접근성을 제공한다. 또한, 본 모델은 실제 환자 장 점막의 구조와 기능을 효과적으로 모사할 수 있어 염증성 장질환을 포함한 다양한 장 질환의 병태생리 연구뿐만 아니라, 후보 물질의 효능 및 안전성을 평가하는 데 유용하게 활용될 수 있다.

METHODS OF DETECTING MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS

Resumen de: WO2026064841A1

The present invention relates in part to methods of detecting Mycobacterium avium subsp. paratuberculosis in ruminant animals and markers for use in such methods.

N-ACYL AMIDES AND ANALOGS

Resumen de: WO2026072849A2

The present disclosure provides pharmaceutical compositions, dosage forms comprising the pharmaceutical composition, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, and treating colorectal cancer in a subject in need thereof, comprising administering the pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.

Method of diagnosing a dysbiosis

Resumen de: AU2026201512A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS). eb e b

Preparation method of non-metal magnetic resonance imaging nano diagnosis and treatment agent with controllable morphology

Resumen de: CN121754690A

The invention belongs to the technical field of magnetic resonance imaging nano diagnosis and treatment agents, and particularly relates to a preparation method of a shape-controllable nonmetal magnetic resonance imaging nano diagnosis and treatment agent. According to the preparation method, 2-(perfluorooctyl) ethyl methacrylate (HDFDMA) and methacrylic acid-2, 2, 6, 6-tetramethyl-4-piperidinyl ester (m-TEMPO) are taken as monomers to prepare shape-controllable sugarcoated haw-shaped nano-particles (WNPT), electronegative tannic acid (TA) is loaded after oxidation, and the shape-controllable sugarcoated haw-shaped nano-particles are prepared through a polymerization-induced self-assembly method. The nanometer diagnosis and treatment agent TA (at) WNPT with a magnetic resonance imaging (MRI) function and a colitis treatment function is obtained. According to the method disclosed by the invention, polymerization and assembly are synchronously carried out under the condition of high concentration, and the morphology, size and surface chemical characteristics of the nanoparticles are accurately regulated and controlled. It is proved for the first time that in the nonmetal MRI probe, compared with spherical particles, the sugarcoated haw-shaped structure can remarkably improve the MRI performance.

DIETARY MACRO/MICRONUTRITIONAL COMPOSITIONS AND APPLICATIONS THEREOF

Resumen de: US20260083739A1

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.

Methods and Treatment Involving Excess Free LIGHT

Resumen de: US20260085112A1

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.

CFDNA AS BIOMARKER FOR INFLAMMATORY BOWEL DISEASES

Resumen de: WO2024236584A1

Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.

C3-HNE ASSAY

Resumen de: WO2024240709A1

The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.

Urine marker for ulcerative colitis as well as analysis method and application thereof

Resumen de: CN121721169A

The ulcerative colitis urine marker can be effectively used for diagnosis and treatment monitoring of ulcerative colitis, and is non-invasive, high in sensitivity and accurate and reliable in result. The ulcerative colitis urine marker at least comprises one of an immune globulin kappa connecting region 1, an immune globulin kappa variable region 6-21 and the like; the urine marker can be used for disease monitoring and at least comprises one of protein 4 rich in glutamic acid, presumed teratoma-derived growth factors 3 and the like.

Biomarker for ulcerative colitis and colorectal cancer related to ulcerative colitis and application of biomarker

Resumen de: CN121718633A

The invention discloses a biomarker for ulcerative colitis and colorectal cancer related to the ulcerative colitis and application of the biomarker, and belongs to the field of molecular biological technology and medicine. The invention discloses an effect of E3 ubiquitin ligase TRIM50 in ulcerative colitis and colorectal cancer related to the ulcerative colitis. The key regulation effect of TRIM50 in UC and UC-CRC is found and verified for the first time, and the potential of TRIM50 as a novel auxiliary detection biomarker and a therapeutic target is defined. The expression level of TRIM50 can be used as a specific biomarker of UC and UC-CRC, and is applied to early screening of diseases, disease assessment or prognosis; targeted regulation of the expression or activity of TRIM50 is expected to become a new strategy for inhibiting the malignant progress of UC-CRC, and a solid theoretical basis and a screening direction are provided for developing innovative drugs.

Biomarker combination and application thereof in predicting risk of Crohn disease

Resumen de: CN121718631A

The invention relates to the technical field of biological medicines, and particularly discloses a biomarker composition and application thereof in predicting the risk of Crohn's disease. The reagent is at least used for detecting more than one group of biomarkers in a first group, a second group and a third group, the first group of biomarkers at least comprises two of APOC1, CDH13, CNDP1, CPB2, MEGF8 and RARRES1, the second group of biomarkers at least comprises two of ALAD, ENPP2, ITIH4, NAV2, PRG2 and SLIT2, and the third group of biomarkers at least comprises two of CFP, GLIPR2, IGHV3-13, PRDX1, SIAE and SNX25. Predictive and/or diagnostic kits developed based on these biomarkers can distinguish healthy individuals, preclinical, early and progression Crohn's disease risks.

Application of HIF-1a in inhibition of HvKp liver abscess in high glucose state

Resumen de: CN121695122A

The invention belongs to the technical field of biomedical research, and particularly relates to an effect of HIF-1a in liver abscess caused by high-toxicity klebsiella pneumoniae infection in a high glucose state. The invention aims to solve the main problem of providing a treatment target for liver abscess caused by high-toxicity klebsiella pneumoniae infection related to diabetes mellitus. As a transcription factor for regulating in-vivo balance, HIF-1a participates in maintaining the integrity of an epithelial barrier, and it is proved that HIF-1a is not reported in type 2 diabetes mellitus in alcoholic hepatitis, inflammatory bowel disease and other models through the anti-inflammatory and antimicrobial functions of immune cells. Modeling finds that the expression of HIF-1a in a type 2 diabetes mellitus combined high-virulence klebsiella pneumoniae infection model is reduced, and inflammation can be obviously relieved after intervention by adding an HIF-1a activating agent. HIF-1a is prompted to be capable of serving as a treatment target of the diabetes-related high-toxicity klebsiella pneumoniae liver abscess.

Application of ZEB1 in analysis and treatment of Crohn disease related diseases

Resumen de: CN121700056A

The invention belongs to the technical field of biology, and relates to application of ZEB1 in analysis and treatment of Crohn disease related diseases. Specifically, the invention discloses application of a reagent for detecting the expression level of ZEB1 in preparation of a product for analyzing the severity of Crohn's disease and the risk and severity of intestinal fibrosis stenosis, and application of ZEB1 in preparation of an animal model of Crohn's disease complicated with intestinal fibrosis or DNBS chronic colitis complicated with intestinal fibrosis, and application of ZEB1 in preparation of an animal model of Crohn's disease complicated with intestinal fibrosis or DNBS chronic colitis complicated with intestinal fibrosis. The reagent for inhibiting ZEB1 expression is applied to preparation of products for inhibiting Crohn's disease complicated with intestinal fibrosis or stenosis. The invention determines that ZEB1 can be used as a biomarker of intestinal fibrosis of Crohn's disease, the expression level of ZEB1 is associated with the risk and severity of intestinal fibrosis or intestinal fibrosis stenosis complicated by Crohn's disease, and a new method is provided for clinically evaluating the risk and severity of disease. Meanwhile, it is clear that ZEB1 can be used as a target spot for treating Crohn's disease complicated with intestinal fibrosis or intestinal fibrosis stenosis.

ANTI-TL1A ANTIBODY THERAPEUTIC METHODS

Resumen de: US20260078194A1

The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

GENE-BASED DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE

Resumen de: JP2026048696A

The present invention provides methods of predicting a subject's likelihood of developing Inflammatory Bowel Disease (IBD) and methods of diagnosing Inflammatory Bowel Disease (IBD) in a subject. Further provided are methods of identifying genes/loci associated with disease states such as IBD, CD, and/or UC.SOLUTION: A method of predicting a subject's likelihood of developing inflammatory bowel disease, the method comprising: Identifying a genotype of a subject for a risk allele of a gene/locus; and predicting a high likelihood of developing IBD in the subject after detection of the risk allele; or predicting a low likelihood of developing IBD in the subject if the risk allele is not detected.SELECTED DRAWING: FIG. 8C

DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS

Resumen de: WO2024227011A1

Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.

METHOD OF TREATMENT

Resumen de: WO2024227232A1

The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.

PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING VARIOUS INFLAMMATORY DISORDERS

Resumen de: JP2026041895A

Provided are methods of treating, preventing and/or delaying the progression of various chronic inflammatory disorders including: (1) type 2 diabetes; (2) acute respiratory distress syndrome; (3) chronic autoimmune inflammatory disorders; (4) inflammatory bowel disease; (5) metabolome-mediated diseases; and (6) hyperphagia disorders.SOLUTION: A method is provided comprising orally administering a pharmaceutical composition comprising a denatonium salt. Further provided is a pharmaceutical composition for the treatment and prevention of various inflammatory conditions that can be tracked by pro-inflammatory biomarkers comprising a denatonium salt that delivers a total daily dose of about 20 mg to about 5000 mg BID to an adult human. Preferably, the denatonium salt is selected from the group consisting of denatonium acetate, denatonium citrate, denatonium maleate, denatonium saccharide and denatonium tartrate.SELECTED DRAWING: None

Methods and systems for diagnosing inflammatory bowel disease (IBD)

Resumen de: CN121620703A

The present invention relates to methods and kits for diagnosing inflammatory bowel disease (IBD) in a subject. The diagnostic method is based on the detection of fecal calprotectin and at least one other fecal biomarker selected from the group consisting of PGRP-S and MMP-8 in a fecal sample from a subject. In a preferred embodiment, the obtained fecal biomarker concentration data is analyzed by supervising a machine learning diagnostic model, and classified as being affected or not affected by IBD.

COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL TESTING OF STOOL

Resumen de: US20260060660A1

The present disclosure provides improved methods of processing a fecal sample by a human subject in which the fecal sample is collected at home and subsequently delivered to a medical diagnostics laboratory. As described herein, the means of collecting and processing the fecal sample can desirably reduce the number of steps undertaken by the human subject, including avoiding steps of removing or separating the fecal sample into multiple portions. Furthermore, the human subject does not have to perform an immunological test (e.g., a fecal immunochemical test (FIT) or an immunochemical fecal occult blood test (iFOBT)) at home.

AGENTS AND METHODS DIRECTED TO DISEASE-ASSOCIATED CELLS

Resumen de: WO2026047225A1

Provided herein are agents and methods suitable for the treatment of inflammatory diseases of the intestine. For instance, agents and methods are provided for the treatment of inflammatory bowel disease, Crohn's disease, ulcerative colitis, Celiac disease, and colitis-associated colorectal cancer.

Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease

Resumen de: AU2026201149A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn’s disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and 5 kits for predicting the response to the therapy of the inflammatory bowel disease. eb e b

PRÜFKÖRPER SOWIE VERFAHREN, PRÜFSTAND UND VERWENDUNG EINES PRÜFKÖRPERS ZUM ERMITTELN EINER MECHANISCHEN BELASTBARKEIT EINES UMHÜLLUNGSSYSTEMS FÜR ERDVERLEGTE STAHLROHRE

Nº publicación: DE102024124516A1 05/03/2026

Solicitante:

DENSO HOLDING GMBH & CO [DE]

Resumen de: DE102024124516A1

Ein Prüfkörper (10), ibs. zum Eindrücken in einen zu prüfenden Gegenstand (12), der bsw. ein Umhüllungssystem für erdverlegte Stahlrohre (14) ist, hat die Gestalt eines Pyramidenstumpfes, Kegelstumpfes oder einer Halbkugelschicht mit einer Grundfläche (10g) und einer Deckfläche (10d), wobei- die Projektion der Deckfläche auf die Grundfläche innerhalb der Grundfläche liegt;- die Deckfläche parallel zu der Grundfläche ist.Ein Verfahren zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst, dass- der Prüfkörper mit der Deckfläche voran von außen gegen das Umhüllungssystem gemäß einem vorbestimmten Wegverlauf und/oder Kraftverlauf gedrückt wird;- die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfasst wird;- die Belastbarkeit abhängig von der erfassten Eindringtiefe ermittelt wird.Ein Prüfstand (16) zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst- ein Haltesystem (18);- eine Materialprüfmaschine (20), die den Prüfkörper mit der Deckfläche voran gegen das Umhüllungssystem drücken kann;- eine Messeinrichtung (22), die die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfassen kann;- eine Steuereinrichtung (24), die gemäß dem Verfahren die Materialprüfmaschine und die Messeinrichtung ansteuern und die Belastbarkeit ermitteln kann.Der Prüfkörper wird zum Ermitteln der mechanischen Belastbarkeit gemäß dem Verfahre